Our top pick for
Tiziana Life Sciences PLC is a biotechnology business based in the US. Tiziana Life Sciences shares (TLSA) are listed on the NASDAQ and all prices are listed in US Dollars. Tiziana Life Sciences employs 8 staff and has a market cap (total outstanding shares value) of 0.00.
|52-week range||$1.04 - $6.14|
|50-day moving average||$2.81|
|200-day moving average||$3.17|
|Wall St. target price||$9.50|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$-0.07|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|Gross profit TTM||$0|
|Return on assets TTM||-82.38%|
|Return on equity TTM||-804.99%|
|Market capitalisation||$234.6 million|
TTM: trailing 12 months
There are currently 48,062 Tiziana Life Sciences shares held short by investors – that's known as Tiziana Life Sciences's "short interest". This figure is 115% up from 22,353 last month.
There are a few different ways that this level of interest in shorting Tiziana Life Sciences shares can be evaluated.
Tiziana Life Sciences's "short interest ratio" (SIR) is the quantity of Tiziana Life Sciences shares currently shorted divided by the average quantity of Tiziana Life Sciences shares traded daily (recently around 267011.11111111). Tiziana Life Sciences's SIR currently stands at 0.18. In other words for every 100,000 Tiziana Life Sciences shares traded daily on the market, roughly 180 shares are currently held short.
However Tiziana Life Sciences's short interest can also be evaluated against the total number of Tiziana Life Sciences shares, or, against the total number of tradable Tiziana Life Sciences shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Tiziana Life Sciences's short interest could be expressed as 0% of the outstanding shares (for every 100,000 Tiziana Life Sciences shares in existence, roughly 0 shares are currently held short) or 0% of the tradable shares (for every 100,000 tradable Tiziana Life Sciences shares, roughly 0 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Tiziana Life Sciences.
Find out more about how you can short Tiziana Life Sciences stock.
We're not expecting Tiziana Life Sciences to pay a dividend over the next 12 months.
Tiziana Life Sciences's shares were split on a 2499:1000 basis on 30 July 2020. So if you had owned 1000 shares the day before before the split, the next day you'd have owned 2499 shares. This wouldn't directly have changed the overall worth of your Tiziana Life Sciences shares – just the quantity. However, indirectly, the new 60% lower share price could have impacted the market appetite for Tiziana Life Sciences shares which in turn could have impacted Tiziana Life Sciences's share price.
Over the last 12 months, Tiziana Life Sciences's shares have ranged in value from as little as $1.04 up to $6.14. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Tiziana Life Sciences's is -0.0028. This would suggest that Tiziana Life Sciences's shares have been inversely-correlated to the average (for this exchange) – so when the broader market trended up or down, Tiziana Life Sciences has bucked the trend.
Tiziana Life Sciences Plc, a clinical stage biotechnology company, focuses on the discovery and development of molecules and related diagnostics to treat diseases in oncology and immunology in the United Kingdom. The company's product pipeline includes Foralumab (TZLS-401), a human anti-CD3 monclonal antibody for the treatment of autoimmune and inflammatory diseases, such GvHD, ulcerative colitis, Crohn's disease, multiple sclerosis, type-1 diabetes, inflammatory bowel diseases, psoriasis, and rheumatoid arthritis; and Milciclib (TZLS-201), which is an orally bioavailable, small molecule inhibitor of cyclin-dependent kinases and Src family kinases for the treatment of hepatocellular carcinoma. It also develops Anti IL-6r (TZLS-501), a human anti-interleukin-6 receptor monoclonal antibody for the treatment of IL6-induced inflammation, primarily to treat hospitalized COVID-19 patients with severe respiratory symptoms; and StemPrintER, a multi-gene signature assay intended for use in patients diagnosed with estrogen-receptor positive ER+/HER2 negative breast cancers. The company was founded in 2013 and is headquartered in London, the United Kingdom. Tiziana Life Sciences Plc is a subsidiary of Planwise Group Limited. .
Everything we know about the TC Bancshares IPO, plus information on how to buy in.
Everything we know about the Soulgate IPO, plus information on how to buy in.
Everything we know about the Alzamend Neuro IPO, plus information on how to buy in.
Everything we know about the Singular Genomics Systems IPO, plus information on how to buy in.
Everything we know about the Golden Sun Education Group Limited IPO, plus information on how to buy in.
Everything we know about the Phillips Edison & Company IPO, plus information on how to buy in.
Everything we know about the FIGS IPO, plus information on how to buy in.
Everything we know about the DLocal Limited IPO, plus information on how to buy in.
Everything we know about the Torchy’s Tacos IPO, plus information on how to buy in.
Everything we know about the Dutch Bros Coffee IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.